NEWS & HIGHLIGHTS
Engineered immune cells target broad range of pediatric solid tumors in mice
In mouse studies, a Stanford-led team has developed an engineered immune cell that eliminates several types of childhood tumors. The study includes senior author, Crystal Mackall, MD, professor of pediatrics and of medicine, and several authors who are members of the MCHRI.
Predicting, preventing preterm births
Each year, 15 million babies worldwide are born prematurely, arriving at least three weeks before their due dates. Stanford’s top obstetricians, neonatologists, geneticists, microbiologists, immunologists, epidemiologists, health policy experts, and bioengineers are working together to help more babies arrive safely.
SPARK helps academic researchers bring new drugs for rare diseases to market
Stanford’s fast-growing drug-development program and MCHRI’s funded partner, SPARK, has given hundreds of academic researchers around the world the training and connections to get their discoveries out of labs and into the hands of doctors and patients. Read the news story and check Stanford Medicine’s summer article about SPARK.